Silence Therapeutics PLC (SLN) — Cash Flow Reinvestment Rate
Silence Therapeutics PLC (SLN) has a Cash Flow Reinvestment Rate of 43.45x as of June 2026, reinvesting $64.94 Million (capex $3.00 plus investments $64.94 Million) from operating cash flow of $1.49 Million. See SLN FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Silence Therapeutics PLC Cash Flow Reinvestment Rate (2019–2021)
Historical reinvestment intensity for Silence Therapeutics PLC across 2 annual periods. For the full cash flow conversion analysis, see cash efficiency ratio of Silence Therapeutics PLC.
Annual Cash Flow Reinvestment Rate for Silence Therapeutics PLC (2019–2021)
Year-by-year capital reinvestment analysis for Silence Therapeutics PLC. See Silence Therapeutics PLC leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (USD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2021 | 1.28x | $11.80 Million | $9.19 Million | $1.80 Million | ▼ -85.2% |
| 2019 | 8.70x | $15.02 Million | $1.73 Million | $9.00K | — |